Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Wiskott Aldrich syndrome


Other Names for this Disease
  • WAS
  • Eczema thrombocytopenia immunodeficiency syndrome
  • Immunodeficiency 2
  • IMD 2
  • Aldrich syndrome
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

News & Events


NCATS Co-Sponsored Conferences

  • Primary Immune Deficiency Treatment Consortium (PIDTC) Scientific Workshop, Thursday, April 07, 2011 - Saturday, April 09, 2011
    Location: San Francisco, CA
    Description: This was a 3-day meeting. Participation at the workshop was by invitation and included representatives from each of the centers participating at PIDTC as well as representatives of CIBMTR, USIDNET, NIAID, ORDR, EBMT, and ESID. This was meant to favor collaboration and promote international collaborative trials in the field of these rare disorders. Special attention was paid to invitation of young investigators at a senior stage in their training or at the beginning of their academic careers. The meeting was open to representatives of the patient advocacy groups that are active in the field of primary immune deficiencies (PIDs) with the intent of promoting communication and collaboration. The results of the meeting will be published in a peer-reviewed journal.

  • The First Wiskott-Aldrich Syndrome Families and Investigators Conference, Friday, July 30, 2010 - Sunday, August 01, 2010
    Location: Hilton Chicago Indian Lakes Resort and Conference Center, Bloomingdale, Illinois
    Description: Conference goals were to (1) gather families affected by Wiskott-Aldrich syndrome (WAS) together in a nonmedical setting to share experiences with each other and present concerns to experts in immunology, BMT, and genetics; (2) review research achievements in WAS diagnosis, treatment (including BMT approaches and gene therapy), post-transplant outcomes (reconstitution and side effects of chemotherapy), and management of medical complications and family psychological issues; (3) develop and prioritize outstanding questions for future research; and (4) coordinate with planned efforts for a national WAS registry.

Other Names for this Disease
  • WAS
  • Eczema thrombocytopenia immunodeficiency syndrome
  • Immunodeficiency 2
  • IMD 2
  • Aldrich syndrome
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.